Autologous bone marrow stem cell transplantation for the treatment of type 2 diabetes mellitus

被引:41
|
作者
Wang Li [1 ]
Zhao Shi [1 ]
Mao Hong [1 ]
Zhou Ling [1 ]
Wang Zhong-jing [1 ]
Wang Hong-xiang [1 ]
机构
[1] Huazhong Univ Sci & Technol, Tongji Med Coll, Cent Hosp Wuhan, Dept Endocrinol, Wuhan 430014, Hubei, Peoples R China
关键词
bone marrow stem cells; transplantation; hyperbaric oxygen therapy; diabetes mellitus; INSULIN-PRODUCING CELLS; PANCREATIC BETA-CELLS; HYPERBARIC-OXYGEN; IN-VIVO; THERAPY; DIFFERENTIATION; ACID;
D O I
10.3760/cma.j.issn.0366-6999.2011.22.005
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Background Autologous peripheral stem cell transplantation was first reported in 2007 to treat type 1 diabetes mellitus (DM) and achieved encouraging effect, but whether similar outcome can be achieved in type 2 DM is not well demonstrated. The objective of this study was to determine the effect of combination of autologous bone marrow stem cell transplantation (BMT) and hyperbaric oxygen treatment on type 2 DM. Methods The study involved 31 patients with type 2 DM (aged 33 to 62 years) from January 2009 to January 2011 in the Central Hospital of Wuhan, China. Clinical variables (body mass index, duration of DM, insulin requirement, oral hypoglycemic drugs, time free from insulin, time free from oral drugs) and laboratory variables (hemoglobin A1c (HbA1c)), mononuclear cells infused, and C-peptide in four time points) were assessed. Purified bone marrow stem cells were infused into major pancreatic arteries. Follow-up was performed at the 30, 90, 180, 360, 540 and 720 days (mean 321 days) after BMT. Results Mean HbA1c values showed a significant reduction during follow-up in all patients after BMT. It decreased by more than 1.5% (from 8.7% to 7.1%) as quickly as at 30 days after BMT. Afterwards mean HbA1c fluctuated between plus or minus 0.5% until 24 months rather than declined continuously. At 90 days after the combined therapy C-peptide increased significantly compared with baseline (P < 0.0001). But in other time points C-peptide was similar with baseline data (P>0.3). All patients had insulin and/or oral hypoglycemic drugs reduced to different levels. The dose of insulin of 7 patients (7/26, 27%) reduced for a period of time after BMT. Conclusions Combined therapy of intrapancreatic BMT and hyperbaric oxygen treatment can improve glucose control and reduce the dose of insulin and/or oral hypoglycemic drugs in type 2 DM patients, but it only improve pancreatic beta-cell function transiently. Further randomized controlled clinical trials involved more patients will be required to confirm these findings and the mechanism needs to be illustrated deeply. Chin Med J 2011;124(22):3622-3628
引用
收藏
页码:3622 / 3628
页数:7
相关论文
共 50 条
  • [1] Autologous bone marrow stem cell transplantation for the treatment of type 2 diabetes mellitus
    WANG LiZHAO ShiMAO HongZHOU LingWANG Zhongjing and WANG Hongxiang Department of EndocrinologyCentral Hospital of WuhanTongji Medical CollegeHuazhong University of Science and Technology WuhanHubei China
    中华医学杂志(英文版), 2011, (22) : 3622 - 3628
  • [2] Efficacy of Autologous Bone Marrow-Derived Stem Cell Transplantation in Patients With Type 2 Diabetes Mellitus
    Bhansali, Anil
    Upreti, Vimal
    Khandelwal, N.
    Marwaha, N.
    Gupta, Vivek
    Sachdeva, Naresh
    Sharma, R. R.
    Saluja, Karan
    Dutta, Pinaki
    Walia, Rama
    Minz, Ranjana
    Bhadada, Sanjay
    Das, Sambit
    Ramakrishnan, Santosh
    STEM CELLS AND DEVELOPMENT, 2009, 18 (10) : 1407 - 1415
  • [3] Combination treatment of autologous bone marrow stem cell transplantation and hyperbaric oxygen therapy for type 2 diabetes mellitus: A randomized controlled trial
    Estrada, Esteban J.
    Luis Decima, Jose
    Bortman, Guillermo
    Roberti, Javier
    Beatriz Romero, Elida
    Samaja, Gustavo
    Rodriguez Saavedra, Aldo
    Martinez, Gerardo
    Gutierrez, Samuel
    CELL TRANSPLANTATION, 2019, 28 (12) : 1632 - 1640
  • [4] AUTOLOGOUS BONE MARROW-DERIVED STEM CELLS TRANSPLANTATION IN TYPE I DIABETES MELLITUS
    Gaipov, Abduzhappar
    Turebekov, Zaiyrkhan
    Serebrennikova, Dina
    Kozina, Larisa
    Askarov, Manarbek
    Tuganbekova, Saltanat
    NEPHROLOGY DIALYSIS TRANSPLANTATION, 2016, 31 : 217 - 217
  • [5] A type 2 diabetes mellitus patient was successfully treated by autologous bone marrow-derived stem cell transplantation: A case report
    Phuong Thi-Bich Le
    Nguyen Phu-Van Doan
    Phan Van Tien
    Dang Ngo Chau Hoang
    Ngoc Kim Phan
    Phuc Van Pham
    BIOMEDICAL RESEARCH AND THERAPY, 2019, 6 (01): : 2966 - 2969
  • [6] Combined Treatment of Intrapancreatic Autologous Bone Marrow Stem Cells and Hyperbaric Oxygen in Type 2 Diabetes Mellitus
    Estrada, Esteban J.
    Valacchi, Fabian
    Nicora, Eduardo
    Brieva, Sergio
    Esteve, Claudio
    Echevarria, Laura
    Froud, Tatiana
    Bernetti, Karina
    Cayetano, Shari Messinger
    Velazquez, Omaida
    Alejandro, Rodolfo
    Ricordi, Camillo
    CELL TRANSPLANTATION, 2008, 17 (12) : 1295 - 1304
  • [7] Administration of Autologous Mesenchymal Stem Cell Transplantation for Treatment of Type 1 Diabetes Mellitus
    Esfahani, Ensieh Nasli
    Ghavamzadeh, Ardeshir
    Mojahedyazdi, Nika
    Hashemian, Seyyedjafar
    Alimoghadam, Kamran
    Aghel, Narjes
    Nikbin, Behrouz
    Larijani, Bagher
    IRANIAN JOURNAL OF PUBLIC HEALTH, 2015, 44 : 55 - 68
  • [8] LONG TERM SAFETY AND EFFICACY OF AUTOLOGOUS STEM CELL TRANSPLANTATION FOR THE TREATMENT OF TYPE 2 DIABETES MELLITUS
    Singh, L.
    Jain, V.
    Sharma, P.
    Singh, S.
    Ramesh, S.
    Maurya, R.
    Raghav, S. K.
    CYTOTHERAPY, 2017, 19 (05) : S24 - S24
  • [9] RESULTS OF THE AUTOLOGOUS MESENCHYMAL STEM CELL TRANSPLANTATION IN PATIENTS WITH TYPE 1 DIABETES MELLITUS AND TYPE 2 DIABETES MELLITUS
    Ulyanova, O.
    Baigenzhin, A.
    Askarov, M.
    Kozina, L.
    Karibekov, T.
    Boltanova, A.
    DIABETES TECHNOLOGY & THERAPEUTICS, 2022, 24 : A181 - A181
  • [10] Autologous bone marrow mononuclear cell (ABMMC) transplantation in type 1 and type 2 insulin dependent diabetes mellitus (IDM).
    Carrasco-Yalan, Antonio A.
    Femandez-Vina, Roberto
    Castillo-Aguirre, Jorge
    Rios, Hugo
    More, L.
    Gomez, N.
    Chirino, Samuel
    Alvarez, Marcos
    Aranda, M.
    Arroyo, M.
    Rafael, J.
    Patel, A. N.
    Tuma-Mubarack, Jorge
    BLOOD, 2007, 110 (11) : 1078A - 1078A